HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA May Put Hold On Lead Acetate Hair-Dye Rule; Manufacturer Combe Demands Hearing

Executive Summary

Grecian Formula marketer Combe likens the process and calculations that informed FDA’s final rule against lead acetate to “a child’s game of telephone.” Environmental Defense Fund warns that if FDA grants Combe’s request – which the NGO suspects is unavoidable – it intends to cross-examine the company’s witnesses about consumer complaints and their handling in the firm’s past.

You may also be interested in...



Lead Acetate Ban A Go As US FDA Denies Combe’s Request For Hearing

Lead acetate’s use as a color additive in cosmetic products will no longer be authorized in the US beginning on 6 January 2022, and the agency will exercise enforcement discretion for a year afterward. A 2018 hearing request from hair dye marketer Combe Inc. was denied by the agency on 7 October.   

Rep. Pallone’s Discussion Draft For Cosmetics Reform Closely Mirrors Reintroduced Feinstein/Collins Bill

A bipartisan proposal from new House Energy & Commerce chair Frank Pallone and Rep. John Shimkus, R-Ill., is a near-facsimile of the reintroduced Personal Care Products Safety Act in the Senate. This could set the stage for simultaneous consideration and expeditious movement in both chambers of Congress.

Senator Seeks Trove Of Talc/Asbestos Docs From J&J; FDA On Status Of Lead Acetate Rule; Beauty News In Brief

The Senate Health Committee’s ranking member is “troubled” by a recent Reuters article, requesting numerous documents from J&J related to talc-asbestos testing and the firm’s communications with FDA and consumers on the subject. More beauty news in brief.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel